-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/scope-communicating-evolving-evidence-white-paper_0.pdf
June 01, 2025 - White Paper: Living Systematic Reviews: Practical Considerations for Adapting Scope and Communicating the Evolving Evidence
White Paper
Living Systematic Reviews: Practical Considerations
for Adapting Scope and Communicating the Evolving
Evidence
White Paper
Living Systematic Reviews: Practical Conside…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/breast-abnormalities-tests-update_disposition-comments.pdf
February 13, 2012 - Comparative Effectiveness Research Review Disposition of Comments Report
http://effectivehealthcare.ahrq.gov/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productID=960
Published Online: February 13, 2012
Comparative Effectiveness Research Review Disposition of Comments Report
Research…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/mental-illness-adults-prisons_executive.pdf
August 01, 2013 - N = 468)
Unknown Precise for reduction in
arrests for crimes other
than parole violations at 6
month
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-235-pharma-nonpharm-ptsd-update-appendix-g-1.xlsx
May 29, 2025 - 2011 Yes Yes No Yes No No Yes Yes Yes Yes Yes Yes Yes Medium-low Wait list randomized after 3 month
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/back-pain-treatment_clinician.pdf
November 01, 2016 - have shown that improvements
in pain (mean reduction to 58% of initial pain scores)
occurred in 1 month
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-e-surv-report-1-nonopioid-pharmacol-chronic-pain.xlsx
May 29, 2025 - NPP
Table E-1. Neuropathic pain study characteristics
Author, Year
Country
Trial Type
Quality Rating Type(s) of Pain Demographics Other Population Characteristics N Randomized
N Analyzed Intervention Duration (Weeks) Funding Source
Hussain, 2021
Pakistan
Placebo-controlled
Fair NPP (DPN) Age, mean: 45
Female: 0%
R…
-
effectivehealthcare.ahrq.gov/sites/default/files/diabetic-neuropathy-disposition-170707.pdf
March 24, 2017 - we initially graded the evidence as
moderate given the consistency of the results
and long-term (6-month … We initially graded the evidence as moderate
given the consistency of the results and long-
term (6-month … we initially graded the evidence as
moderate given the consistency of the results
and long-term (6-month
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/diabetic-neuropathy-disposition-170707.pdf
March 24, 2017 - we initially graded the evidence as
moderate given the consistency of the results
and long-term (6-month … We initially graded the evidence as moderate
given the consistency of the results and long-
term (6-month … we initially graded the evidence as
moderate given the consistency of the results
and long-term (6-month
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/tympanostomy-tubes-disposition.pdf
May 05, 2017 - Age 1 month to 18 years
old is a wide age range; a
correspondingly wide range of
developmental changes … P26,
Limes 42 – 51: This
paragraph uses two
different metrics-risk
difference in episodes par
month … and -10.5 dB
respectively, with 95%
credible intervals that
exclude a null effect in the
1 to 3 month
-
effectivehealthcare.ahrq.gov/sites/default/files/tympanostomy-tubes-disposition.pdf
May 05, 2017 - Age 1 month to 18 years
old is a wide age range; a
correspondingly wide range of
developmental changes … P26,
Limes 42 – 51: This
paragraph uses two
different metrics-risk
difference in episodes par
month … and -10.5 dB
respectively, with 95%
credible intervals that
exclude a null effect in the
1 to 3 month
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/surveillance-report-2-noninvasive-nonpharma.pdf
April 01, 2022 - That report included randomized controlled
trials (RCTs) reporting outcomes at least 1 month following … full-text review was inadequate duration of followup postintervention in nine trials (i.e.,
followup <1-month … Chronic headache is defined as 15 or
more days each month for at least 12
weeks or history of headache … months), intermediate term (≥6 to
<12 months) and long term (≥12
months); focus on longer term (>12
month … • Studies with <1 month followup after treatment
B-5
PICOTS Inclusion Exclusion
Studies
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/peripheral-nerve-block-protocol.pdf
November 18, 2023 - Peripheral Nerve Blocks for Postoperative Pain Management in Cardiothoracic Surgery
Evidence-based Practice Center Systematic Review Protocol
Project Title: Peripheral Nerve Blocks for Postoperative Pain Management in Cardiothoracic
Surgery
I. Background and Objectives for the Systematic Review
Millio…
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/adhd_research-protocol.pdf
August 10, 2010 - Evidence-based Practice Center Systematic Review Protocol
Source: www.effectivehealthcare.ahrq.gov
Published Online: August 10, 2010
Evidence-based Practice Center Systematic Review Protocol
Project Title: Attention Deficit Hyperactivity Disorder:
Effectiveness of Treatment in At-risk Preschoolers; Long…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/renal-artery-stenosis_overview.pdf
June 24, 2014 - CER 5 Renal Artery Stenosis NSD SJ Clean
Renal Artery Stenosis
Nomination Summary Document
Results of Topic Selection Process & Next Steps
§ The topic, Renal Artery Stenosis,…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/gerd-disposition-120104.pdf
April 01, 2011 - EE
maintenance - A 6-month, multicenter, double-blind, randomized,
placebo-controlled trial evaluated … Two-thirds, or 66%, of patients
treated with dexlansoprazole 30 mg remained healed over the 6-
month … Histology – The long-term histological safety of dose-titrated
lansoprazole was evaluated in an 82-month … trial program (6
randomized, double-blind, controlled studies and one randomized,
open-label, 12-month
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/pelvic-pain-surveillance-151130.pdf
July 10, 2015 - Painful symptoms and perception of stress were recorded 1 month after surgery. … MEASURE(S): Perceived stress
scale (PSS) and visual analog scale for painful symptoms before and 1 month … The intensity of chronic pelvic pain and dyspareunia significantly decreased at 6-month treatment in … At 6-month treatment, the number of migraine attacks was lower than at baseline in group POP (p=0.002 … The intensity of migraine attacks was significantly different between baseline and 6-month treatment
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/chronic-urinary-retention_disposition-comments.pdf
September 15, 2014 - Disposition of Comments for Chronic Urinary Retention: Comparative Effectiveness and Harms of Treatments
Comparative Effectiveness Review Disposition of Comments Report
Research Review Title: Chronic Urinary Retention: Comparative Effectiveness
and Harms of Treatments
Draft review available for public…
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/wireless-motility-capsule_research-protocol.pdf
March 14, 2012 - Evidence-based Practice Center Systematic Review Protocol
Source: www.effectivehealthcare.ahrq.gov
Published Online: March 14, 2012
Evidence-based Practice Center Systematic Review Protocol
Project Title: Wireless Motility Capsule Versus Other Diagnostic Technologies for
Evaluating Gastroparesis and Cons…
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/linking-evidence-reviews-methods_0.pdf
October 01, 2018 - agreement was reached on the basic content, we refined the content and slides over an
approximately 1-month … including the evaluation
process) involved about four conference calls and email communication over a 2-month
-
effectivehealthcare.ahrq.gov/sites/default/files/obesity-horizon-scan-high-impact-1506.pdf
June 01, 2015 - prescription-drug prices, GoodRx, liraglutide under the
name Saxenda costs up to about $1,200 per month … dosing, after the 5-week dose-escalation schedule, one carton of liraglutide represents about a 1-
month … between $200 and $500
(lorcaserin, naltrexone/bupropion, orlistat, phentermine/topiramate) for a 1-month